CTGF Specific Neutra™ Antibody Products

Connective Tissue Growth Factor (CTGF) stands as a matricellular protein within the CCN family of extracellular matrix-linked heparin-binding proteins. Operating at the nexus of various biological processes, CTGF contributes significantly to cell adhesion, migration, proliferation, angiogenesis, and skeletal development. Its involvement extends to wound healing and plays a crucial role in nearly all fibrotic pathologies, with connections to diseases such as Systemic Scleroderma and Renal Fibrosis. Pertinent pathways related to CTGF encompass Apoptotic Pathways in Synovial Fibroblasts and the PAK Pathway.

Its Gene ID: 1490, UniProtKB ID: P29279, and OMIM ID: 121009.

CTGF Related Signaling Pathways

Upon secretion from cells, CTGF engages with a diverse array of molecules, including growth factors, cytokines, matrix proteins, and receptors. These interactions intricately modify signal transduction pathways, exerting both positive and negative influences that subsequently induce alterations in cellular responses. The repercussions of this signaling modulation encompass variations in cell adhesion, angiogenesis, migration, differentiation, and vascular permeability, including the formation and activation of myofibroblasts. Additionally, these interactions contribute to extracellular matrix remodeling and deposition, collectively orchestrating tissue remodeling and inducing changes in organ structure.

Fig.1 CTGF influences diverse signaling pathways and processes crucial in pathophysiology.¹

Targeting CTGF for Therapeutic Interventions in Various Disorders

Delve into the pivotal role of CTGF in bone disorders. Uncover how neutralizing CTGF antibodies offer promising avenues for mitigating bone-related ailments and revolutionizing OA treatment strategies.

• Inhibition of MENK Expression Decrease by Neutralizing CTGF Antibody in Compressive Force-Loaded Osteocytes

Recent research highlights the pivotal involvement of neuropeptides in bone metabolism. Methionine enkephalin (MENK), a neuropeptide, exerts dual regulatory effects on apoptosis, contingent upon cell type. In experiments, the inhibitory effect of a neutralizing CTGF antibody countered the compressive force-induced reduction of MENK. Administration of MENK mitigated the increase in osteocyte apoptosis observed in compressive force-loaded parietal bones. Furthermore, the application of a neutralizing CTGF antibody effectively prevented the decrease in MENK expression in compressive force-loaded osteocytes.

Fig.2 Inhibition of MENK expression decreased by neutralizing anti-CTGF antibody in compressive force-loaded osteocytes.²

• Anti-CTGF Antibodies may Help Novel OA Treatment

In osteoarthritis (OA) joints, the expression of CTGF markedly surpasses that observed in healthy joints. Deviations in CTGF expression levels can precipitate cartilage degeneration. Notably, CTGF assumes a pivotal role in both physiological and pathological cartilage states, underscoring its potential as a therapeutic target for OA. At the protein level, the therapeutic emphasis on targeting CTGF predominantly revolves around CTGF antibody interventions. Several monoclonal antibodies targeting CTGF have already advanced to phase II clinical trials for the treatment of PIF and DMD.

Creative Biolabs provides a diverse array of anti-CTGF antibody products, meticulously engineered through recombinant techniques. Moreover, customization options are accessible to tailor CTGF-based recombinant antibodies or neutralizing antibodies, catering to unique requirements.

REFERENCES

1. Lipson, Kenneth E., et al. "CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis." Fibrogenesis & tissue repair. Vol. 5. BioMed Central, 2012. Distributed under Open Access license CC BY 2.0, without modification.
2. Sogi, Chisumi, et al. "Methionine enkephalin suppresses osteocyte apoptosis induced by compressive force through regulation of nuclear translocation of NFATc1." Journal of Bone and Mineral Research Plus 4.7 (2020): e10369. Distributed under Open Access license CC BY 4.0, with modification. The image was modified by extracting and using only Part A of the original image.